Northside Hospital Cancer Institute

Immunotherapy Program

The Immunotherapy Program at Northside Hospital Cancer Institute has been an authorized CAR T-cell treatment center since 2018. We now offer all four FDA-approved CAR T-cell products for B-cell malignancies.

1. **Breyanzi**®, **Yescarta**® and **Kymriah**® for patients with R/R **large B-cell lymphomas** including transformed follicular lymphoma
2. **Tecartus**® for patients with R/R **mantle cell lymphoma**
3. **Yescarta**® for patients with R/R **follicular lymphoma**
4. **Kymriah**® for patients with R/R **B-lineage acute lymphoblastic leukemia**

R/R Aggressive Large B-Cell Lymphoma

Breyanzi®, lisocabtagene maraleucel, is the newest FDA-approved CD19-directed genetically modified autologous CAR T-cell immunotherapy.

- A unique product in that it is administered as separate CD8+ and CD4+ CAR T-cell components at equal target doses, resulting in a consistent administered CD8+ and CD4+ CAR T-cell dose and low variability in the CD8+/CD4+ ratio
- Indicated for the treatment of adult patients with R/R large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma, transformed follicular lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B

Deep, rapid and durable responses including:

- Demonstrated a 73% overall response rate and 54% complete response (CR) rate in the large pivotal TRANSCEND NHL 001 trial
- 58% of all patients were alive at 1-year, including 86% of those who achieved a complete response to therapy
- Favorable safety profile with only 2% of patients having high-grade (grade 3 or greater) CRS, and 10% of patients having high-grade neurotoxicity

Breyanzi® (lisocabtagene maraleucel) SUSPENSION FOR IV INFUSION

Mantle Cell Lymphoma

Tecartus® is the first-and-only FDA-approved CD19-directed genetically modified autologous CAR T-cell immunotherapy indicated for the treatment of adult patients with R/R mantle cell lymphoma after first line therapy.

Deep, rapid and durable responses including:

- 87% overall response rate and 62% complete response (CR) in the ZUMA-2 pivotal trial
- 1-month median time to response (range: 0.8–3.1 months)
- The median duration of response was not reached at a median study follow-up of 12.3 months

Indolent Follicular Lymphoma

Yescarta® is the first-and-only FDA-approved CD19-directed genetically modified autologous CAR T-cell immunotherapy indicated for the treatment of adult patients with indolent R/R follicular lymphoma after two or more lines of systemic therapy.

Deep, rapid and durable responses including:

- 91% objective response rate and 60% complete remission rate in the ZUMA -5 pivotal trial
- 1-month median time to response
- 12-month progression-free survival and overall survival rates were 74% and 93%, respectively

Referring patients **early** can assist in optimal treatment planning due to varying product manufacturing times, which can take between 2-4 weeks.

Please call 404-255-1930 to initiate a referral or to speak to a physician.

NORTHSIDE HOSPITAL

CANCER INSTITUTE

BUILT TO BEAT CANCER